Chronic Spontaneous Urticaria Pipeline Market Research 2025: Comprehensive Outlook on Existing and Forthcoming CSU Therapies

Key market opportunities in the Chronic Spontaneous Urticaria pipeline involve the development of diverse therapeutic approaches, including novel monoclonal antibodies and Bruton’s tyrosine kinase inhibitors. With over 25 drugs in various stages and significant collaborations, there's potential for innovation and addressing unmet needs.

Dublin, Oct. 22, 2025 (GLOBE NEWSWIRE) -- The "Chronic Spontaneous Urticaria - Pipeline Insight, 2025" has been added to ResearchAndMarkets.com's offering.

The report offers an in-depth analysis of over 20 companies and 25 pipeline drugs within the Chronic Spontaneous Urticaria (CSU) landscape. The study includes detailed profiles of both clinical and nonclinical stage products, encompassing therapeutics assessments segmented by product type, development stage, route of administration, and molecule type, as well as information on inactive pipeline products.

Chronic Spontaneous Urticaria (CSU), also referred to as chronic idiopathic urticaria, manifests unpredictably without a clear external trigger. It often involves autoimmune mechanisms leading to the activation of mast cells. These cells release histamine and other mediators, resulting in symptoms such as itchy welts and angioedema. Though autoimmune thyroid disease, infections, or stress can be associated factors, many cases remain idiopathic. Effective management includes limiting investigations to necessary tests like differential blood count and C-reactive protein levels while utilizing treatments such as antihistamines and omalizumab.

The report outlines current and emerging therapeutic solutions for CSU and details ongoing R&D efforts by highlighting challenges, opportunities, and the impact of these new therapies. Treatments are in various development phases, from preclinical to advanced stages, with descriptions including mechanisms of action, clinical trials, and approvals.

Highlighted emerging drugs in the report include:

• Remibrutinib by Novartis : A highly selective, oral BTK inhibitor shown to be well-tolerated in Phase II trials, Remibrutinib blocks histamine release, providing rapid efficacy for moderate to severe cases of CSU. It shows potential as a complement to injectable biologics like omalizumab.
• Barzolvolimab by Celldex Therapeutics: A monoclonal antibody that targets the KIT receptor, crucial in mast cell activation. Successful Phase II results indicate potential for broader applications beyond CSU, including other mast cell-driven disorders.
• JYB1904 by Jemincare: A novel anti-IgE monoclonal antibody reducing free IgE levels and showing promise in Phase I trials with a more extended half-life than existing treatments.
• YH35324 by Yuhan Corporation: Engineered to neutralize free IgE, this fusion protein offers a long-acting alternative demonstrated to outperform current options in early trials.

Additionally, the report includes insights into significant collaborations, mergers, licensing activities, and unmet needs in CSU treatment. Key players such as Novartis , Celldex Therapeutics, and Yuhan Corporation are driving new solutions into upcoming clinical phases.

Overall, the report provides a comprehensive outlook on existing and forthcoming CSU therapies, offering valuable insights for stakeholders and researchers involved in the development of new CSU treatments.

Key Topics Covered:

Introduction

Executive Summary

Chronic Spontaneous Urticaria: Overview

• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Chronic Spontaneous Urticaria - Analytical Perspective

Late Stage Products (Phase III)

• Comparative Analysis

Barzolvolimab: Celldex Therapeutics

• Product Description
• Research and Development
• Product Development Activities

Mid Stage Products (Phase II)

• Comparative Analysis

JYB1904: Jemincare

• Product Description
• Research and Development
• Product Development Activities

Early Stage Products (Phase I)

• Comparative Analysis

YH35324: Yuhan Corporation

• Product Description
• Research and Development
• Product Development Activities

Preclinical and Discovery Stage Products

• Comparative Analysis

Drug Name : Company Name

• Product Description
• Research and Development
• Product Development Activities

Inactive Products

• Comparative Analysis

Chronic Spontaneous Urticaria Key Companies

Chronic Spontaneous Urticaria Key Products

Chronic Spontaneous Urticaria - Unmet Needs

Chronic Spontaneous Urticaria - Market Drivers and Barriers

Chronic Spontaneous Urticaria - Future Perspectives and Conclusion

Chronic Spontaneous Urticaria Analyst Views

Chronic Spontaneous Urticaria Key Companies

• Novartis
• Hangzhou Highlightll Pharmaceutical Co., Ltd
• Celldex Therapeutics
• Jemincare
• Yuhan Corporation
• United BioPharma
• Septerna
• Recludix Pharma

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/epkpdc

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood, Senior  Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900